重组(酵母)乙型肝炎疫苗阻断乙型肝炎病毒母婴传播和加强免疫效果—9年随访观察  

Interruption of Perinatal Transmission of Hepatitis B Virus (HBV) With a Recombiant Yeast-derived Hepatitis B Vaccine and Immunogenicity—9 Years of Follow-up

作　　者：李艳萍[1] 李荣成[1] 杨进业[1] 李琼池 农艺[1] 李坚龙 徐桂生[4] 梁争论[5] 吴晓音[5] 李河民[5] 

机构地区：[1]广西壮族自治区疾病预防控制中心,南宁530021 [2]桂林市南溪山医院,广西壮族自治区桂林541000 [3]桂林市疾病预防控制中心,广西壮族自治区桂林541001 [4]柳州市疾病预防控制中心,广西壮族自治区柳州545001 [5]中国药品生物制品检定所,北京100050

出　　处：《中国计划免疫》2005年第2期83-85,共3页Chinese Journal of Vaccines and Immunization

摘　　要：目的　观察重组(酵母)乙型肝炎(乙肝)疫苗阻断乙肝病毒(HBV)母婴传播的长期效果,探讨阻断HBV母婴传播的最佳免疫策略。方法　对母亲血清乙肝病毒表面抗原(HBsAg)和乙肝病毒膜抗原(HBeAg)同时阳性、新生儿期全程接种乙肝疫苗后HBsAg阴性的2 73名儿童进行9年血清学追踪观察。结果　共观察到12人HBsAg阳转,1～9岁HBsAg阳性率0 72 %～6 .98% ,低或无应答儿童9岁内17 .78%发生HBsAg阳转;免疫后9年保护性水平乙肝病毒表面抗体(抗 HBs)阳性率仍维持>6. 0 % ;3～5岁加强免疫儿童抗体阳性率及抗体水平高于未加强免疫儿童。结论　重组(酵母)乙肝疫苗对阻断HBV母婴传播具有良好的远期免疫效果。母亲HBsAg和HBeAg双阳性的幼儿在3～4岁时需加强免疫。低或无应答新生儿有较高的HBsAg阳转危险性。Objective To assess the long-term efficacy of recombinant yeast-derived hepatitis B vaccine in infants born to HBsAg and HBeAg carrier mother. Methods A total of 273 neonates born to HBsAg,HBeAg both positive mothers were vaccinated with 5,5,5 μg doses of recombinant yeast-derived hepatitis B vaccine by 0,1, and 6 months schedule.They were all followed for 1-9 years after the primary vaccination. Results Twelve infants (6.63%) become HBsAg positively conversed in 9 year after primary vaccination,and the positive Rate of HBsAg in 1-9 year was 0.72%-6.8%,17.8% of child in no/lowly-respond become HBsAg positively.At the ninth year the positive rates of anti-HBs were 60% above.Anti-HBs positive rates and immunity level were higher at 3-5 year old by repetition immunity than others. Conclusion The recombinant yeast-derived hepatitis B vaccine have good immunogenecity and long-term protective efficacy to HBV interruption of perinatal transmission,a booster dose seems necessary in aged 3-4 years to the mother with HBsAg and HBeAg.It is high-risk to become HBsAg positively in the baby of norespones to hepatitis B vaccine.

关 键 词：重组(酵母)乙型肝炎疫苗 阻断乙型肝炎病毒母婴传播 效果 

分 类 号：R186[医药卫生—流行病学] R512.62[医药卫生—公共卫生与预防医学]